

Amendments to the Specification

Please amend the specification as indicated below without prejudice or disclaimer.

Replacement pages corresponding to these amendments are attached herewith.

5 *Please amend lines 12-16 on page 2 as shown below:*

Figure 1. BFA4 cDNA sequence (SEQ ID NO.:1).

Figure 2. BFA4 amino acid sequence (SEQ ID NO.:2).

Figure 3. BCY1 nucleotide (A; SEQ ID NO.:3) and amino acid (B; SEQ ID NO.:4) sequences.

Figure 4. BFA5 cDNA sequence (SEQ ID NO.:5).

10 **Figure 5.** BFA5 amino acid sequence (SEQ ID NO.:6).

Please amend the paragraph at page 14, lines 14-18 as shown below:

A fusion motif may enhance transport of an immunogenic target to an MHC processing compartment, such as the endoplasmic reticulum. These sequences, referred to as transduction or 15 transcytosis sequences, include sequences derived from HIV tat (see Kim et al. 1997 J. Immunol. 159:1666), *Drosophila* antennapedia (see Schutze-Redelmeier et al. 1996 J. Immunol. 157:650), or human period-1 protein (hPER1; in particular, SRRHCRSKAKRSRHH (SEQ ID NO.: 105)).

Please amend Table III found on pages 30-31 as shown below:

TABLE III
BF45 Peptide Pools

Peptide Group	CLP number	Sequence	SEQ ID	Peptide Group	CLP number	Sequence	SEQ ID
BF45 Group 1	2983	LMDMQTFKA	<u>7</u>	BF45 Group 6	3033	FESSAKIQV	<u>53</u>
	2984	KVSIPTKAL	<u>8</u>		3034	GVTAEHYAV	<u>54</u>
	2985	SIPTKALEL	<u>9</u>		3035	RVTSNKTKV	<u>55</u>
	2986	LELKNEQTL	<u>10</u>		3036	TVSQKDVCV	<u>56</u>
	2987	TVSQKDVCV	<u>11</u>		3037	KSQEPAFH	<u>57</u>
	2988	SVPNKALEL	<u>12</u>		3038	KVLAENTM	<u>58</u>
BF45 Group 2	2989	CETVSQKD	<u>13</u>	BF45 Group 7	3039	MLKLEIATL	<u>59</u>
	2990	KINGKLEES	<u>14</u>		3040	EILSWVAKL	<u>60</u>
	2991	SLVEKTPDE	<u>15</u>		3041	MLKKEIAML	<u>61</u>
	2992	SLCETVSQK	<u>16</u>		3042	LLKEKNEEI	<u>62</u>
	2993	EIDKINGKL	<u>17</u>		3043	ALRIQDIEL	<u>63</u>
	2994	MLLQQQNIVDV	<u>18</u>		3044	KIREELGRI	<u>64</u>
	2995	NNWLLQQQLV	<u>19</u>		3045	TLKLKEESEL	<u>65</u>
	2996	FLVDRKCOL	<u>20</u>		3046	ILNEKIREE	<u>66</u>
	2997	YLLHENCM	<u>21</u>		3047	VLKKKLSEA	<u>67</u>
	2998	SLEFESSAKI	<u>22</u>		3048	GTSDDKIQCL	<u>68</u>
	2999	KITIDIHFL	<u>23</u>		3049	GADINLVDV	<u>69</u>
	3000	QLQSKNMW	<u>24</u>		3050	ELCSVRLTL	<u>70</u>
	3001	SLDQKLFQL	<u>25</u>		3051	SVESNLNQV	<u>71</u>
	3002	FLLIKNANA	<u>26</u>		3052	SILKINLYA	<u>72</u>

Peptide Group	CLP number	Sequence	SEQ ID	Peptide Group	CLP number	Sequence	SEQ ID
BFA5 Group 3	3003	KILDTVHSC	<u>27</u>	BFA5 Group 8	3053	KTPDEAASL	<u>73</u>
	3004	SLSKILDTV	<u>28</u>		3054	ATCGMVKSI	<u>74</u>
	3005	ILDSGADI	<u>29</u>		3055	LSHGVIEV	<u>75</u>
	3006	KVMEINREV	<u>30</u>		3056	EIAMLKLEI	<u>76</u>
	3007	KLLSHGAVI	<u>31</u>		3057	AELQMTLKL	<u>77</u>
	3009	AVYSEIILSV	<u>32</u>		3058	VFAADICGV	<u>78</u>
	3010	KMNVDVST	<u>33</u>		3060	PAIEMQNSV	<u>79</u>
	3011	ILSVVAKLL	<u>34</u>		3061	EIFNYNNHL	<u>80</u>
	3012	VLAVENTMVL	<u>35</u>		3062	ILKEKNAEL	<u>81</u>
BFA5 Group 4	3013	KLSKNHQNNT	<u>36</u>	BFA5 Group 9	3063	QLVHAKKA	<u>82</u>
	3014	SLTPLLLSI	<u>37</u>		3065	NIQDAQKRT	<u>83</u>
	3015	SQYSGQLKV	<u>38</u>		3066	NLVDVYGNM	<u>84</u>
	3016	KELEVQQL	<u>39</u>		3067	KCTALMLAV	<u>85</u>
	3017	QIMEYIRKL	<u>40</u>		3068	KIQCLEKAT	<u>86</u>
	3018	AMLKLEIAT	<u>41</u>		3069	KIAWEKKET	<u>87</u>
	3019	VLHQPLSEA	<u>42</u>		3070	IAWEKKEDT	<u>88</u>
	3020	GLLKATCCGM	<u>43</u>		3071	VGMILLQQNV	<u>89</u>
	3021	GLLKANCCGM	<u>44</u>		3072	VKTGCVARV	<u>90</u>
BFA5 Group 5	3022	QOLEQALRI	<u>45</u>	BFA5 Group 10	3074	ALHYAVYSE	<u>91</u>
	3023	CMLKKEIAM	<u>46</u>		3075	QMKKKFCVL	<u>92</u>
	3024	EQMKKKFCV	<u>47</u>		3076	ALQCHQEAC	<u>93</u>
	3025	IQDIELKSV	<u>48</u>		3077	SEQIVEFLL	<u>94</u>
	3026	SVPNKAFFEL	<u>49</u>		3078	AVIEVHNKA	<u>95</u>
	3027	SIYQKVMEI	<u>50</u>		3079	AVTCGFHHI	<u>96</u>
	3028	NLYAGDAL	<u>51</u>		3080	ACLQRKMNV	<u>97</u>
	3029	AVQDHDDGIV	<u>52</u>		3081	SLVEGTSDK	<u>98</u>

Please amend the paragraph on page 32, lines 16-32 as shown below:

In addition to ELISPOT analysis, human T cells activated by BFA5 peptides were assayed to determine their ability to function as CTL. The cells were activated using peptide-pulsed dendritic cells followed by CD40 ligand-activated B cells (5 rounds of stimulation). The experiment shown was performed with isolated PBMC from HLA-A*0201⁺ donor AP31. Isolated T cells were tested in ⁵¹Cr-release assays using peptide-loaded T2 cells. The % specific lysis at a 10:1, 5:1, and 1:1 T-cell to target ratio is shown for T2 cells pulsed with either pools of BFA5/NYBR-1 peptides or with individual peptides. The graph shows CTL activity induced against targets loaded with a c non-specific HLA-A*0201-binding HIV peptide (control) followed by the CTL activity against the peptide pool (Pool 1 etc.) and then the activity induced by individual peptides from the respective pool to the right. A high level of cytotoxicity was observed for some peptides at a 1:1 E:T ratio. CTL activity (percent specific lysis) induced by the control HIV peptide was generally <10%. Similar results were obtained with another PBMC donor expressing HLA-A*0201 (AP10). A large number of BFA5 peptides trigger T cell-mediated cytotoxicity of BFA5 peptide-loaded target cells. **Table IV** lists those peptides having immunogenic properties. Five peptides (LMDMQTFKA (SEQ ID NO.:7), ILIDSGADI (SEQ ID NO.:29), ILSVVAKLL (SEQ ID NO.:34), SQYSGQLKV (SEQ ID NO.:38), and ELCSVRLTL (SEQ ID NO.:70)) were found to induce both IFN- γ secretion and CTL activity in T cells from both donors.

Please amend Table IV beginning on page 32, line 33 as shown below:

TABLE IV
Immunoreactive peptides from BFA5

	BFA5 peptides eliciting high IFN- γ release (>200 spots/100,000 cells)		BFA5 peptides inducing CTL lysis of pulsed cells	
<u>SEQ ID NO.</u>	Donor AP10	Donor AP31	Donor AP10	Donor AP31
<u>7</u>	LMDMQTFKA	LMDMQTFKA	LMDMQTFKA	LMDMQTFKA
<u>8</u>	KVSIPTKAL			<u>KVSIPTKAL</u>
<u>9</u>	SIPTKALEL			<u>SIPTKALEL</u>
<u>11</u>	TVSQKDVCL			
<u>12</u>	SVPNKALEL			
<u>21</u>	YLLHENCML	YLLHENCML	YLLHENCML	
<u>24</u>	QLQSKNMWL	QLQSKNMWL		QLQSKNMWL
<u>28</u>	SLSKILDV	SLSKILDV		SLSKILDV
<u>29</u>	ILIDSGADI	ILIDSGADI	ILIDSGADI	ILIDSGADI
<u>30</u>	KVMEINREV			
<u>32</u>	AVYSEILSV			
<u>34</u>	ILSVVAKLL	ILSVVAKLL	ILSVVAKLL	ILSVVAKLL
<u>37</u>	SLTPLLLSI	SLTPLLLSI		SLTPLLLSI
<u>38</u>	SQYSGQLKV	SQYSGQLKV	SQYSGQLKV	SQYSGQLKV
<u>40</u>	QIMEYIRKL	QIMEYIRKL		QIMEYIRKL
<u>49</u>	SVPNKAFEL			
<u>51</u>	NLNYAGDAL	NLNYAGDAL		
<u>54</u>		GVTAEHYAV		
<u>57</u>		KSQEPAFHI		
<u>59</u>	MLKLEIATL	MLKLEIATL		MLKLEIATL
<u>61</u>		MLKKEIAML		
<u>63</u>	ALRIQDIEL			
<u>67</u>		VLKKKLSEA		
<u>70</u>	ELCSVRLTL	ELCSVRLTL	ELCSVRLTL	ELCSVRLTL
<u>72</u>	SLKINLNYA	SLKINLNYA		SLKINLNYA
<u>74</u>	ATCGMKVSI		ATCGMKVSI	
<u>77</u>	AELQMTLKL		AELQMTLKL	AELQMTLKL
<u>78</u>		VFAADICGV		
<u>81</u>	ILKEKNAEL	ILKEKNAEL		
<u>84</u>	NLVDVYGNM		NLVDVYGNM	
<u>85</u>	KCTALMLAV			

Please amend lines 5-10 on page 34 as shown below:

BFA5(1-23) KLH-MTKRKKTINLNQDAQKRTALHW (CLP-2977; SEQ ID NO:99)
BFA5(312-334) KLH-TSEKFTWPAKGRPRKIAWEKKED (CLP-2978; SEQ ID NO:100)
BFA5(612-634) KLH-DEILPSESKQKDYEENSWDTESL (CLP-2979; SEQ ID NO:101)
BFA5(972-994) KLH-RLTLNQEEEKRRNADILNEKIRE (CLP-2980; SEQ ID NO: 102)
BFA5(1117-1139) KLH-AENTMLTSKLKEKQDKEILEAEI (CLP-2981; SEQ ID NO: 103)
BFA5(1319-1341) KLH-NYNNHLKNRIYQYEKEKAETENS (CLP-2982; SEQ ID NO: 104)

Please amend line 26 on page 34 as shown below:

Both bands were found to be consistent with the polyclonal antibodies tested in this analysis.